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TuberculosisA B S T R A C T
Objective/background: Tuberculosis (TB) is a worldwide public health problem. It is a conta-
gious and grave disease caused by Mycobacterium tuberculosis. Current drugs such as isoni-
azid, pyrazinamide, and rifampicin used for the treatment of tuberculosis are potentially
hepatotoxic and can lead to drug hepatitis. In order to improve the follow-up of TB patients
in Cameroon, we carried out a study which aimed to evaluate the hepatotoxicity risk fac-
tors associated with anti-TB drugs.
Methods: The studies were performed on 75 participants who had visited the Loum District
Hospital located in the littoral region of Cameroon for their routine consultation. Partici-
pants have been selected based on pre-established criteria of inclusion and exclusion. Prior
to the informed consent signature, patients were given compelling information about the
objective and the result output of the study. They were questioned about antioxidant food
and alcohol consumption as well as some clinical signs of hepatotoxicity such as fever,
nausea, vomiting, and tiredness. The collected blood was tested for the determination of
biochemical markers (transaminases and C-reactive protein) using standard spectrophoto-
metric methods.
Results: Biochemical analysis of samples showed a significant increase (p < .05) of aspartate
aminotransferase and alanine aminotransferase values in TB patients coinfected with
human immunodeficiency virus/AIDS (33.28 ± 16.58 UI/L and 30.84 ± 17.17 UI/L, respec-
tively) compared with the respective values of the controls (16.35 ± 5.31 UI/L and 16.45
± 4.83 UI/L). Taking individually, the liver injury patient percentage of TB patients was sig-
nificant compared to TBC when considering alanine aminotransferase and aspartate
aminotransferase parameters. When considering risk factors, antioxidant food, Dschang,
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parameters, whereas an opposite situation was observed with alcohol consumption
between TB-coinfection and TB patients. Regarding the C-reactive protein results, the per-
centage of positive tests was very high among coinfected patients (40%) compared with the
control (15%). The interactions between parameters related to alcohol consumption and
intake of antioxidant foods showed a slight decrease in activity comparedwith interactions
without food.
Conclusion: The results showed that human immunodeficiency virus status and alcohol
consumption constitutes aggravating factors for the occurrence of hepatic toxicity. In addi-
tion, the consumption of antioxidant foods simultaneously with TB drugs help in reducing
the hepatotoxic effects of these drugs.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction Material and methodsTuberculosis (TB) is an infectious disease caused by the bac-
terium called Mycobacterium tuberculosis. It usually affects
the lungs (pulmonary TB) but can affect other organs, such
as bones and lymph nodes (extrapulmonary TB). The disease
is spread through air when TB patients expel the bacteria, by
coughing for example [1]. TB remains a major global health
problem in Africa and Asia. It affects the health of millions
of people annually throughout the world and ranks as the
second disease leading to death among infectious diseases
worldwide after human immunodeficiency virus (HIV)/AIDS
[2]. The World Health Organization estimated in 2012 that
there were up to 8,600,000 new TB cases and 1.3 million
deaths. Just under the 1.0 million people who died were
HIV-negative and 0.3 million deaths were people coinfected
with HIV [3]. Most TB cases and deaths occur in men, but
the burden of disease in women is also high. In Cameroon,
approximately 35,000 of TB cases are recorded every year
and 40% of these patients are also diagnosed HIV-positive/
AIDS. Between 2009 and 2013, among the 100,000 habitants
hospitalized in Cameroon, 238 were suffering from TB,
including 83 cases of pulmonary TB, with a mortality rate of
30.94% [4]. The recommended treatment regimen for new
cases of TB includes four drugs (isoniazid [I], rifampicin [R],
ethambutol [E], and pyrazinamide [Z]) for 6 months. Three
of these drugs (I, Z, and R) are potentially hepatotoxic and
can lead to drug-induced hepatitis [3]. A study carry out in
India on the use of different schemes of TB regimen in adults
demonstrated 2.6% liver toxicity with I coadministrated with
R and 1.1% and 1.6% with R and I alone, respectively [5].
Similar studies conducted in Turkey and Singapore showed
that the reintroduction of Z was more likely to lead to a recur-
rence of hepatotoxicity [6]. As hepatotoxicity caused by these
drugs is related to the administration of higher doses of
drugs, a lower daily dose is recommended or a reduction in
the frequency of the drugs to three times weekly [7].
In Cameroon very few studies have been conducted
regarding the potential hepatotoxicity risks of TB treatment
either in TB patients or in coinfected TB/HIV patients.
Therefore, it was important to carry out this study to identify
and understand the hepatotoxic risks of TB drugs in order to
manage the treatment.Ethical consideration
This study was approved by the Ethics Research Committee of
the Cameroon Bioethics Initiative (CAMBIN) located in
Yaounde – Cameroon and the ethical clearance was obtained
under the reference number CBI/317/CARE/CAMBIN. This
approval helped receive authorization from the hospital cen-
ter under the reference number 176/L/MSP/DRSPL/DSL/HDL.
Patient gave ‘‘informed consent” in order to give details relat-
ing to the understanding of the purpose, any profit if involved
in the study, as well as their right to be included or not in the
study.
Patients and drug consumption
Descriptive and analytical retrospective and prospective stud-
ies were conducted in TB patients with ages ranging from
15 years to 65 years, under anti-TB drugs under Directly
Observed Treatment, Short course, visiting Loum District
Hospital. The study was conducted from June 2014 to
February 2015. Composed of some voluntary participants
without TB or/and HIV infection (control), both TB patients
coinfected with HIV/AIDS or not coinfected were included in
the study. The patients fulfilled the following criteria: (1) they
were on anti-TB drugs at least 2 months; (2) were not receiv-
ing any other hepatotoxic drugs parallel with anti-TB treat-
ment as well as without hepatitis B or C; and (3) had normal
findings of liver function parameters at the beginning of the
treatment. TB patients were given a 6-month regimen of four
first-line drugs: I, R, E, and Z divided into two phases:
2 months of RIEZ and 4 months of RI. Coinfected patients
with HIV/AIDS received 9 months divided into two phases:
2 months of I/R/Z ± E and 7 months of I/R. Some hepatotoxic-
ity clinical signs such as fever, nausea, vomiting, and tired-
ness were monitored. Patients were given a questionnaire
about some antioxidant foods and alcohol consumption
levels. Antioxidant food was well explained to the patients
in relation to their physio-pathological situation, to help them
understand that this type of food plays a big role in the elim-
ination of excess of free radicals that can sometimes mediate
hepatotoxicity according to Yew and Leung [8]. Ambreen et al.
Table 1 – Sociodemographic characteristics of the study population.
Characteristics Interval (%)




Alcohol Male patients 25.45*
Female patients 5.45
Note. Chi-square test was used to compare frequencies. y = year.
* Difference is significant at p < .05.
484 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 4 8 2 –4 8 8[9] as well as Yew and Leung [8] revealed that alcohol is one of
the most common risk factors that have been found to be
associated with anti-TB dug-induced hepatotoxicity (DIH).
Follow-up and parameter measurements
Patients were positively diagnosed using a sputum examina-
tion in which bacterium were directly observe under a micro-
scope. To evaluate the occurrence of hepatotoxicity, blood
samples were collected into dried tubes under a temperature
of 4 C and immediately centrifuged at 1509g for 5 min to
obtain serum. This was then kept at 8 C until use. The dif-
ferent sera obtained were used to for biochemical analysis.
Liver function was tested transversally after the treatment.
Liver function parameters (alanine aminotransferase [ALT],
aspartate aminotransferase [AST], and C-reactive protein
[CRP]) were measured in blood serum by utilizing an auto-
analyzer in the pathology lab. Transaminases (AST and ALT)
were determined using spectrophotometry following the
kinetic method previously described. The CRP was measured
qualitatively and semiquantitatively with the slide agglutina-
tion test CRP-latex reagent (Arlington Scientific, Inc.TM, Spring-
ville, UT, USA) in which the particles are coated with anti-
human CRP antibodies. According to Ambreen et al. [9], the
presence of at least one of the following criteria was used to
define anti-TB-DIH: a rise to more than two times the normal
level of CRP, ALT, and/or AST; any increase in ALT and/or AST
above pretreatment levels together with anorexia, nausea,
vomiting, and jaundice. Liver function parameters included
ALT, AST, and CRP. The liver injury patient percentage (LIP)
helps to find people with hepatotoxicity based on the above
criteria.
Statistical analysis
The data collected were entered in Microsoft Office Excel 2007
(Microsoft Corporation Corporate Headquarters Redmond,
WA, USA) and checked for any inconsistencies. Analysis of
variance followed by Tukey post hoc were used to compare
the means of the enzymatic parameters. The interactions
between these biochemical parameters and risk factors (age,
sex, andalcohol)wereanalyzedusingmultivariate testing gen-
eral linearmodel. Chi-square testwasused to compare the fre-
quencies of single factors or interactions. Also, a bivariate
correlationwasmade through the Spearman rho test. Ap value
<.05 was considered significant. All the analysis was carried
out using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA).Results
The baseline characteristics of the patients are given in
Table 1. From the 75 participants in the study, 30 were TB only,
25 were TB coinfected, and there were 20 controls. In this
study men were most represented (60%). The age group
younger than 45 years was the most represented (65.33%)
compared with the group equal or greater than 45 years
(34.67%). The mean age was 37 years for men and 34 years
for women. Taking into account the risk of hepatotoxicity
associated with alcohol intake, it is clear that the frequency
of alcohol consumption was significantly higher (p < .05) in
male patients (25.45%) than in female patients (5.45%).
Table 2 shows variation of parameters ALT, AST, and CRP in
both TBC and TB patients compared with the control group.
There is a significant difference (p < .001) of the mean values
of transaminases (ASTand ALT) in TBC groups comparedwith
the controls and TB-only patients. The same observation was
made with the percentage of positive tests for CRP although
this was not significant. In spite of the fact that some slight
differences were observed between values, it remains clear
that no significant difference is noticeable with reference val-
ues. However, concerning the ALT parameter, nine TBC
patients out of 25 (12%) presented with hepatotoxicity based
on the criteria used (they presented twice with the biochem-
ical parameter values compared with the control). Moreover,
three TB patients out of 30 (10%) presented with hepatotoxic-
ity based on the criteria used (they presented twice with the
biochemical parameter values compared with the control).
Furthermore, the difference between TBC patients and TB
patients is significant (p < .001).
The LIP helps to find people with hepatotoxicity based on
the criteria used (they presented twice with the biochemical
parameter values compared with the control). Concerning
the AST parameter, 10 TBC patients out of 25 (40%) pre-
sented hepatotoxicity based on the criteria used (they pre-
sented twice with the biochemical parameter values
compared with the control). Moreover, three TB patients
out of 30 (10%) presented with hepatotoxicity. Furthermore,
the difference between TBC patients and TB patients is sig-
nificant (p < .05; Table 2). LIP for the food and alcohol con-
sumption between TBC and TB patients is also presented
in the text and tables.
The effects of different factors such as alcohol intake, sex,
and age on the previous biochemical parameters were also
evaluated using multivariate general linear model and the
results presented in Table 3 show that the interaction
Table 2 – Effect of patient group on some biochemical parameters.
Groups (sample size) AST (UI/L) ALT (UI/L) CRP (% of positive tests)
Reference value (35–38) LIP (%) Reference value (35–38) LIP (%)
Control (20) 16.35 ± 5.31a 0.0 16.45 ± 4.83a 0.0 15.0
TB (30) 20.43 ± 15.01a 10 21.3 ± 11.4a 10 36.66
TBC (25) 33.28 ± 16.58b 40* 30.84 ± 17.17b 12* 40.0
Note. The analysis of variance followed by Tukey post hoc were used to compare the means of the enzymatic parameters. The value subscripted
with the same letter in the columns show no significant difference. Chi-square was used to compare the frequencies of liver injury patient
percentage and C-reactive protein between tuberculosis and tuberculosis coinfection. ALT = alanine aminotransferase; AST = aspartate
transaminase; CRP = C-reactive protein; LIP = liver injury patient percentage; TB = tuberculosis; TBC = tuberculosis coinfection.
* Difference is significant at p < .05.
Table 3 – Influence of sex and patient group on some biochemical parameters.
Groups (sample size) AST (UI/L), reference value (35–38) ALT (UI/L), reference value (35–38) CRP (% of positive tests)
Men Women Men Women Men Women
Control (20) 15.71 ± 5.62 15.68 ± 4.88 15.00 ± 5.10 16.67 ± 4.71 12.5 12.5
TB (30) 21.88 ± 17.21 17.91 ± 12.05 18.56 ± 9.8 21.41 ± 10.91 43.75 37.5
TBC (25) 32.07 ± 19.19 31.89 ± 12.96 31.03 ± 18.66 27.82 ± 16.22 43.75 50.0
Note. The interactions between biochemical parameters and risk factor (sex) were analyzed using multivariate testing general linear model.
ALT = alanine aminotransferase; AST = aspartate transaminase; CRP = C-reactive protein; TB = tuberculosis; TBC = tuberculosis coinfection.
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brings about a slight increase of ALT and CRP in men com-
pared with women. The influence of sex on some biochemical
parameters presented in Table 4 shows a nonsignificant dif-
ference on all the parameters studied in the group of patients
consuming alcohol or not compared with controls. The multi-
variate testing general linear model indicated that age was
not a significant (p > .05) risk factor for anti-TB-DIH. Further,
the analysis shown in Table 5 shows that CRP was very high
even though it was not significant in patients aged older than
45 years.
At follow-up of the patients, we observed that certain clin-
ical signs associated with hepatotoxicity were evaluated in
these patients. These results, shown in Table 6, demonstrate
a high percentage gap between the TBC and TB groups for
symptoms (fatigue, fever, nausea, and vomiting). Among
these a significant variation (p < .05) was noted in people with
fever symptoms. However, the percentages of the various
symptoms observed were higher among TB patients com-Table 4 – Influence of alcohol and patient groups on some bioch
Groups (sample size) AST (UI/L), reference value (35–38) ALT
Alcohol LIP (%) No alcohol Alc
Control (20) 15.71 ± 5.62 0.0 15.68 ± 4.88 15.0
TB (30) 21.88 ± 17.21 66.67 17.91 ± 12.05 18.5
TBC (25) 32.07 ± 19.19 50.0* 31.89 ± 12.96 31.0
Note. The interactions between biochemical parameters and risk factor
model. Chi-square was used to compare the frequencies of liver injury
between tuberculosis and tuberculosis coinfected.
ALT = alanine aminotransferase; AST = aspartate transaminase; CRP = C-
losis; TBC = tuberculosis coinfection.
* Difference is significant at p < .05.pared with TBC patients. Furthermore, it was noted that the
time of appearance of these signs was between 10 days and
45 days.
In order to assess the influence of some antioxidants pre-
sent in the diet on the occurrence of hepatotoxicity, the qual-
ity of food consumption (fruits and vegetables) was estimated
in all participants of the various study groups. Table 7 depicts
the influence of diet on risk factors for hepatotoxicity while
taking TB drugs or not, comparedwith the control. Usingmul-
tivariate testing general linear model, from Table 7 it appears
that the interaction between different parameters (ALT, AST,
and CRP) and foods show a slight decrease in different groups
(28.75 ± 14.39 UI and 37.00 ± 17.89 UI for AST). When food is
not taken into account, the values of these parameters
become high (26.25 ± 14.4 UI and 34.57 ± 18.9 UI for AST) but
not significant. The same observation was made with alcohol
consumption. When looking at the percentage of LIP (liver
injury patients) based on the above criteria, it appears from
Table 7 that the percentage of TB patients with LIP decreasesemical parameters.
(UI/L), reference value (35–38) CRP (% of positive tests)
ohol LIP (%) No alcohol Alcohol No alcohol
0 ± 5.10 0.0 16.67 ± 4.71 12.5 12.5
6 ± 9.8 66.67 21.41 ± 10.91 43.75 37.5
3 ± 18.66 55.55* 27.82 ± 16.22 43.75 50.0
s (alcohol) were analyzed using multivariate testing general linear
patient percentage and C-reactive protein when consuming alcohol
reactive protein; LIP = liver injury patient percentage; TB = tubercu-
Table 5 – Effect of age and patient group on some biochemical parameters.
Groups (sample size) AST (UI/L), reference value (35–38) ALT (UI/L), reference value (35–38) CRP (% of positive tests)
<45 y >45 y <45 y >45 y <45 y >45 y
Control (20) 16.5 ± 5.64 17.75 ± 2.87 16.81 ± 5.48 16.5 ± 1.73 4 8
TB (30) 20.76 ± 17.37 19.2 ± 9.04 20.81 ± 9.78 17.7 ± 10.71 20 28
TBC (25) 28.46 ± 15.43 40.5 ± 17.23 25.13 ± 13.87 39.4 ± 19.01 16 24
Note. The interactions between biochemical parameters and risk factors (alcohol) were analyzed using multivariate testing general linear
model. ALT = alanine aminotransferase; AST = aspartate transaminase; CRP = C-reactive protein; TB = tuberculosis; TBC = tuberculosis
coinfection.
Table 6 – Change in some clinical symptoms based on some factors.
Symptoms Groups % Symptoms/alcohol (%) Symptoms/antioxidant food (%)
Tiredness TBC 42.9 44.0 36.0
TB 57.1 60.0 50.0
Fever TBC 6.7 12.0 7.6
TB 93.3* 96.67 88.33
Nausea TBC 20.0 28.0 12.0
TB 80.0 83.33 73.33
Vomiting TBC 20.0 24.0 16.0
TB 80.0 83.33 76.67
Note. Chi-square analysis and multivariate logistic regression. TB = tuberculosis; TBC = tuberculosis coinfection; Symptoms/alcohol = when
taking alcohol into consideration; Symptoms/antioxidant food = when food is taken into consideration.
* Difference is significant at p < .05.
Table 7 – Role of some antioxidant foods on aspartate transaminase (AST), alanine aminotransferase (ALT), and C-reactive
protein (CRP) parameters.
Groups AST (UI/L), reference value (35–38) ALT (UI/L), reference value (35–38) CRP (% of positive tests)
Alt No Alt LIP (%) Alt No Alt LIP (%) Alt No Alt
Controls (20) 16.3 ± 5.31 16.4 ± 5.60 0.0 16.4 ± 5.25 16.5 ± 4.67 0.0 5.88 33.33
TB (30) 19.94 ± 17.50 20.53 ± 12.10 33.33 20.12 ± 9.55 22.23 ± 14.3 66.67 10.0 80.0
TBC (25) 28.75 ± 14.39 37.0 ± 17.89 70.0* 26.25 ± 14.4 34.57 ± 18.9 55.56* 13.33 80.0
Note. The values for transaminases are expressed as means ± standard deviation. Chi-square was used to compare the frequencies of liver
injury patient percentage and CRP when antioxidant food are not consuming between tuberculosis and tuberculosis coinfected.
Alt = antioxidant food; LIP = liver injury patient percentage; TB = tuberculosis; TBC = tuberculosis coinfected.
* Difference is significant at p < .05.
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suming antioxidant food and no alcohol consumption. These
observations are reversed when not consuming antioxidant
food but with a considerable alcohol consumption (Tables 4
and 7).
Discussion
Diet, clinical symptoms, biochemical parameters, and some
risk factors such as alcohol intake, age, and sex, are generally
taken into account whenmonitoring the health of TB patients
in the LoumDistrict Hospital and these parameters were eval-
uated to better understand the effect of the TB drugs on liver
toxicity. The three main drugs usually used by TB patients
(I, Z, and R) are potentially hepatotoxic [3]. ALT and AST are
mainly synthesized in the liver and located in the cytoplasm
and mitochondrion respectively. After synthesis, theseenzymes can be found in the blood in a lower concentration.
The high level of ASTand ALT in serum can explain liver dam-
age [10]. In this study, we found that there was a significant
increase (p < .05) in ALT and AST values among coinfected
and noncoinfected TB patients compared with controls
(Table 2). The elevation of these enzyme activities could be
due to the use of TB drugs. TBC patients showed a slight
increase in ALT and AST activities. In fact, when taking TB
drugs, I hydrolysis by R produces isonicotinic acid releasing
hydrazine. Once this is released it undergoes an acetylation
reaction in the presence of isonicotinic acid to give hydrazine
monoacetyl which subsequently undergoes a cascade of reac-
tions including oxidation which is accelerated by alcohol
intake and produces hepatotoxic compounds [11]. Kone´ [12],
during a comparative study on HIV/TB coinfected patients
in Mali, indicated an acceleration of liver enzymes and pro-
gression to cirrhosis in coinfected patients compared with
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decrease in immune status of HIV patients could be link with
the increase of risk of liver toxicity.
The effects of different factors such as alcohol intake, sex,
and age on these parameters (ALT, AST, and CRP) were also
assessed as well as the role of food or noninteraction with
alcohol. Of all these factors, alcohol had the greatest influ-
ence by increasing the values of these parameters. The same
observation was made with the age factor only for CRP, but
this was not significant. Moreover, the intake of some foods
(fruits and vegetables) decreased the effect of alcohol. Foods
consumed on this medication could be responsible for the
decline of activities/observed frequencies.
The state of malnutrition according to the National
Institute of Nutrition [13] is suggested as a risk factor for
anti-TB drugs inducing hepatotoxicity. The same observation
was made by Khoharo et al. [14] and Senaratne et al. [15] in
their studies showed that diet plays a role in the occurrence
of hepatotoxicity. Moreover, other authors suggested that
hepatotoxicity of TB drugs induced by malnutrition may be
due to the depletion of glutathione reserves, making patients
vulnerable to oxidation and thus to oxidative stress which is a
mediator of hepatotoxicity [7,16,17]. A previous study on
Ethiopian patients with TB and coinfected with HIV demon-
strated that the development of hepatotoxicity due to TB
drugs is significantly associated with a decrease in nutritional
status. This result corroborates with our study which shows
no significant increase in the parameters studied in relation
to alcohol intake. It is therefore important to note that the
foods consumed by patients can have a strong antioxidant
potential and thus protect liver cells against toxicity.
The age group older than 45 years was not significantly
influenced by increasing percentages of positive tests of CRP
in patients compared with controls. Studies conducted by
Durand et al. [18] and Senaratne et al. [15], showed that
advanced age may be a risk factor for hepatotoxicity in TB
treatment. By contrast, studies carried by Marzuki et al. [5],
Javadi et al. [19], and Sharifzadeh et al. [20] showed that
advanced age was not a risk factor for hepatotoxicity in
patients taking anti-TB inducing drugs. This could be
explained not only through compliance with medication
doses and frequencies, but also nutrition that helps cope with
oxidative stress—the main pathway mediated hepatotoxicity
associated with taking TB drugs.
Some patients experienced nausea, vomiting, fatigue, and
fever. This clinical evidence was significant (p < .05) due to the
fact that these patients had not complied with the prescribed
diet and the prescription of alcohol intake. The first clinical
signs of liver toxicity were observed at the interval 10–45 days.
Makhlouf et al. [16] worked on the hepatotoxicity of Z and E in
the treatment of latent TB and also observed similar clinical
manifestations when taking anti-TB-HID in patients within
the 15–60-day time interval.Conclusion
Regarding the results obtained in this study we can conclude
that advanced age (older than 45 years), HIV/AIDS status, and
regular alcohol consumption were identified as factorsaggravating the occurrence of hepatotoxicity when taking
TB drugs. Also, we found that regular consumption of foods
such as fruits and vegetables highly rich in antioxidant mole-
cules reduce the risk of liver dysfunction while taking TB
drugs.
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